Literature DB >> 6534346

Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells.

I P Hayward, P G Parsons.   

Abstract

The anti-tumour methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide (MTIC) increased the thymidine and deoxycytidine pools but not the deoxyguanosine pool in human melanoma cells. Incorporation of deoxyguanosine and deoxyadenosine was strongly inhibited by MTIC due to formation of the decomposition product 5-aminoimidazole-4-carboxamide (AIC). Theophylline, natural nucleosides and sulphydryl compounds did not affect the toxicity of MTIC in either MTIC-sensitive (Mer-) or autologous-resistant (Mer+) melanoma cells. 3-Aminobenzamide (3 mM for 48 h), an inhibitor of ADP-ribosyl transferase, greatly enhanced MTIC toxicity in the resistant compared with the sensitive cell line.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6534346     DOI: 10.1038/icb.1984.57

Source DB:  PubMed          Journal:  Aust J Exp Biol Med Sci        ISSN: 0004-945X


  3 in total

1.  A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.

Authors:  S V Rajkumar; J M Reid; P J Novotny; S L Safgren; B W Scheithauer; P S Johnson; S Nair; R F Morton; A K Hatfield; J E Krook; M M Ames; J C Buckner
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

2.  Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro.

Authors:  B J Jean-Claude; A Mustafa; N D Cetateanu; Z Damian; J De Marte; R Yen; D Vasilescu; T H Chan; B Leyland-Jones
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.

Authors:  J M Lunn; A L Harris
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.